PT  - JOURNAL ARTICLE
AU  - Bryois, Julien
AU  - Calini, Daniela
AU  - Macnair, Will
AU  - Foo, Lynette
AU  - Urich, Eduard
AU  - Ortmann, Ward
AU  - Iglesias, Victor Alejandro
AU  - Selvaraj, Suresh
AU  - Nutma, Erik
AU  - Marzin, Manuel
AU  - Amor, Sandra
AU  - Williams, Anna
AU  - Castelo-Branco, Gonçalo
AU  - Menon, Vilas
AU  - De Jager, Philip
AU  - Malhotra, Dheeraj
TI  - Cell-type specific cis-eQTLs in eight brain cell-types identifies novel risk genes for human brain disorders
AID  - 10.1101/2021.10.09.21264604
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.09.21264604
4099  - http://medrxiv.org/content/early/2021/10/14/2021.10.09.21264604.short
4100  - http://medrxiv.org/content/early/2021/10/14/2021.10.09.21264604.full
AB  - Most expression quantitative trait loci (eQTL) studies to date have been performed in heterogeneous brain tissues as opposed to specific cell types. To investigate the genetics of gene expression in adult human cell types from the central nervous system (CNS), we performed an eQTL analysis using single nuclei RNA-seq from 196 individuals in eight CNS cell types. We identified 6108 eGenes, a substantial fraction (43%, 2620 out of 6108) of which show cell-type specific effects, with strongest effects in microglia. Integration of CNS cell-type eQTLs with GWAS revealed novel relationships between expression and disease risk for neuropsychiatric and neurodegenerative diseases. For most GWAS loci, a single gene colocalized in a single cell type providing new clues into disease etiology. Our findings demonstrate substantial contrast in genetic regulation of gene expression among CNS cell types and reveal genetic mechanisms by which disease risk genes influence neurological disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The consent for use of the human tissue samples in the study was approved by respective IRBs of Amsterdam Brain bank, UK brain bank, ROSMAP and Roche.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA shinyApp to browse the result of this study is available at: https://malhotralab.shinyapps.io/brain_cell_type_eqtl/The full eQTL summary statistics are available on zenodo at: https://doi.org/10.5281/zenodo.5543734All single nuclei RNA-seq and genotypes will be made available after peer-review.https://malhotralab.shinyapps.io/brain_cell_type_eqtl/https://doi.org/10.5281/zenodo.5543734